Financials

v3.24.1.u1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 14,103,120 $ 13,723,681
Investments 106,000,091 7,182,325
Restricted cash 284,950 192,475
Prepaid expenses and other current assets 1,308,336 2,447,549
Total current assets 121,696,497 23,546,030
Restricted cash 384,950 477,425
Property and equipment, net 821,526 973,214
Operating lease right of use assets 2,841,189 3,062,920
Other assets 0 212,804
Total assets 125,744,162 28,272,393
Current liabilities:    
Notes payable 189,818 300,664
Accounts payable 2,081,812 3,178,516
Accrued expenses 9,398,225 11,030,506
Derivative liability 10,882 39,450
Operating lease liabilities, current 1,477,669 1,436,723
Current portion of long-term debt 12,764,915 15,908,214
Total current liabilities 25,923,321 31,894,073
Other long-term liabilities 0 44,411
Operating lease liabilities, noncurrent 2,855,140 3,238,631
Total liabilities 28,778,461 35,177,115
Stockholders' equity    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023. 0 0
Common stock, $0.0001 par value; 300,000,000 shares authorized,10,507,237 and 4,423,683 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 1,050 442
Additional paid-in capital 540,875,910 429,780,375
Accumulated deficit (443,582,754) (436,683,983)
Accumulated other comprehensive loss (328,505) (1,556)
Total stockholders’ equity 96,965,701 (6,904,722)
Total liabilities and stockholders’ equity $ 125,744,162 $ 28,272,393

Source

v3.24.1.u1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 5,761,494 $ 13,388,343
General and administrative 3,861,251 3,908,682
Total operating expenses 9,622,745 17,297,025
Operating loss (9,622,745) (17,297,025)
Other income (expense), net:    
Other income (expense), net 2,909,097 229,507
Interest expense, net (177,015) (678,022)
Change in fair value of derivative liability 28,568 0
Foreign currency exchange gain (loss), net (36,676) 728
Other income (expense), net 2,723,974 (447,787)
Net loss $ (6,898,771) $ (17,744,812)
Earnings Per Share, Basic $ (0.83) $ (4.24)
Earnings Per Share, Diluted $ (0.83) $ (4.24)
Weighted Average Number of Shares Outstanding, Basic 8,310,508 4,181,556
Weighted Average Number of Shares Outstanding, Diluted 8,310,508 4,181,556
Comprehensive loss:    
Net Income (Loss) $ (6,898,771) $ (17,744,812)
Other comprehensive (loss) income :    
Change in unrealized (loss) gain on marketable debt securities (326,949) 57,623
Total other comprehensive (loss) income (326,949) 57,623
Total comprehensive loss $ (7,225,720) $ (17,687,189)

Source

v3.24.1.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net loss $ (6,898,771) $ (17,744,812)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 982,016 1,026,379
Depreciation expense 151,688 181,870
Net amortization on discount of investments (909,495) (201,908)
Loss (gain) on foreign currency transaction 34,475 (2,917)
Amortization of debt discount 187,670 201,123
Change in fair value of derivative liability (28,568) 0
Realized loss on investments 505 1,561
Changes in operating assets and liabilities:    
(Increase) decrease in prepaid expenses and other current assets 1,228,992 (561,219)
Decrease (increase) in other assets 212,804 (27,090)
Decrease in operating lease right of use asset 221,731 195,784
(Decrease) increase in other long-term liabilities (44,411) 2,500,000
Decrease in accounts payable (1,131,178) (848,056)
(Decrease) increase in accrued expenses (1,632,281) 469,050
Decrease in operating lease liabilities (342,545) (304,737)
Net cash used in operating activities (7,967,368) (15,114,972)
Cash flows from investing activities:    
Purchases of investments (105,897,725) (13,308,006)
Proceeds from sales and maturities of investments 7,662,000 18,857,710
Net cash (used in) provided by investing activities (98,235,725) 5,549,704
Cash flows from financing activities:    
Proceeds from issuance of common stock 115,589,985 37,056
Repayment of notes payable (110,846) (150,066)
Repayment of long-term borrowings (2,205,969) 0
Issuance costs paid for common stock financings (6,690,638) 0
Net cash provided by (used in) financing activities 106,582,532 (113,010)
Net increase (decrease) in cash, cash equivalents, and restricted cash 379,439 (9,678,278)
Cash, cash equivalents, and restricted cash at beginning of the period 14,393,581 17,672,615
Cash, cash equivalents, and restricted cash at end of the period 14,773,020 7,994,337
Supplemental disclosure of cash flow information and non-cash transactions:    
Cash paid during the period for interest 547,375 641,458
Proceeds from issuance of common stock not yet received 0 92,689
Common stock issuance costs not yet paid 170,668 0
Issuance of common stock for conversion of convertible debt $ 1,125,000 $ 0

Source